Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUSA and PolyICLC in Advanced Melanoma
NCT06472661Phase 1Recruiting
- Sponsor
- University of Virginia
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of poly-ICLC in melanoma, sponsored by University of Virginia. Primary endpoints: Adverse Events and Pathologic ablation zone at Day 22. Started Sep 2024; status: recruiting.
02
Drugs
poly-ICLC
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06472661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472661.